Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the common sleeping disorder.
3don MSN
We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look ...
Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...
Eli Lilly just gave investors several reasons to cheer.
Eli Lilly And Co. LLY, a top pick for the firm, is projected to see continued growth in its diabetes and obesity ...
Two Dearborn County high school seniors recently learned they are the 2025 recipients of a prestigious Lilly Endowment ...
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...
Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...
Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Akash Tewari has given his Buy rating due to a combination of factors including Eli Lilly & Co’s strategic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback